Spyre Deprioritizes SPY072 Monotherapy in Rheumatoid Arthritis After Mixed Phase II
Spyre Therapeutics reported Week 12 results from the 143-patient Phase II SKYWAY-RA trial of the anti-TL1A antibody SPY072 in moderate-to-severe rheumatoid arthritis. The low-dose arm met the primary DAS28-CRP endpoint and showed nominally significant…
